microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression.
Regulus’ expertise in microRNA therapeutics will be used to discover chemically modified oligonucleotide anti-miRs.
Regulus Therapeutics chief scientific officer Neil W Gibson said GBM is a hazardous disease whose treatment options are very limited.
"At Regulus, we have successfully targeted microRNAs in multiple disease settings and believe that targeting dysregulated microRNAs using chemically modified oligonucleotide anti-miRs provides a potential therapeutic approach for GBM," Gibson added.